| Abstract: | In the management of metastatic prostate cancer, treatment with androgen deprivation therapy, initially with surgery via bilateral orchidectomy and more recently with medical therapy using gonadotropin‐releasing hormone (GnRH) agonists, has remained the key treatment approaches for this disease stage. Notably, patients express a preference towards a medical therapy approach. We present the case study of a patient with symptomatic metastatic prostate cancer treated with the new GnRH antagonist degarelix. |
